Project Grant R41NS143585
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $454K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This $419,375 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, supports research to optimize and validate a novel QTE therapy for treating Friedreich's Ataxia (FRDA), a rare and debilitating neurological disorder. The key products and services being provided under this grant include: Optimization of the QTE therapy dosage and formulation through pharmacokinetic modeling and assessments of drug synergy, bioavailability, and blood-brain...
- This federal Project Grant award of $500,000.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research by Tega Therapeutics Inc. to develop new clinical biomarkers for GM1 gangliosidosis, a lysosomal storage disease. The project aims to confirm whether levels of specific glycan metabolites in urine and/or cerebrospinal fluid reflect changes in...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This $392,863 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research at Duke University to develop therapeutics for Spinocerebellar Ataxia Type 48 (SCA48), a rare genetic neurodegenerative disorder. The researchers will optimize and miniaturize assays to screen for small molecules that can restore the proper folding and...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...
- The University of California, Davis (UC Davis) was awarded a $1,169,064 Cooperative Agreement grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The purpose of this 5-year award is to finalize refinement and validation of a primary clinical outcome assessment, the FXTAS Rating Scale (FXTAS-RS), as well as a set of neurocognitive, motor, and...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. The $1,009,212 award to the Van Andel Research Institute in Grand Rapids, MI will fund pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to enhance the activity of the...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Augusta University Research Institute, Inc. The objective is to develop and evaluate engineered exosomes carrying neuron-targeting peptides and a therapeutic protein (neuroglobin) for treating ischemic stroke. The research will: 1) characterize the engineered exosomes and assess their...
- This $490,501 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), supports Janusq LLC, a startup biotech company spun out of Case Western Reserve University, in developing a peptide-based therapy called HV-3 for the treatment of Huntington's disease (HD). The key objectives of this 16-month project are to: (1) perform preliminary safety and toxicity...
- The federal Project Grant award R15NS137207, valued at $389,851, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports research at the Florida Institute of Technology (Florida TECH) to investigate the role of the RPM-1 signaling network in tau protein-related neurodegeneration using a C. elegans tauopathy model. The proposed research...